Welcome to our dedicated page for Pro-Dex Colo SEC filings (Ticker: PDEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pro-Dex, Inc. (NASDAQ: PDEX) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Pro-Dex operates in the surgical and medical instrument manufacturing industry, focusing on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and its filings give detailed insight into how this business is structured and managed.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include discussions of net sales, gross profit, operating expenses, operating income, and the effects of product mix, repair programs, and costs such as tariffs. These filings also describe the importance of Pro-Dex’s largest customer, shipments of next generation orthopedic handpieces, and repair revenue for legacy products, all of which are central to understanding the company’s revenue profile.
Users can also examine current reports on Form 8-K, where Pro-Dex discloses material events such as earnings announcements, contract developments, executive and director compensation decisions, equity incentive awards, and the results of its annual meeting of shareholders. For example, recent 8-K filings detail restricted share grants under the company’s equity incentive plan, discretionary cash bonuses for executives, and shareholder voting outcomes on director elections, auditor ratification, and amendments to the equity incentive plan.
In addition, the proxy statement filed on Form DEF 14A provides information on corporate governance, board composition, executive compensation, and proposals submitted to shareholders. Together, these documents offer a comprehensive view of Pro-Dex’s financial reporting, governance practices, and key risks and opportunities.
On Stock Titan, Pro-Dex filings are updated from EDGAR and accompanied by AI-powered summaries that highlight the main points of lengthy 10-Ks, 10-Qs, and 8-Ks, helping readers quickly understand what has changed. The platform also makes it easier to navigate to filings related to executive and director compensation, equity plans, and other matters that can influence shareholders’ evaluation of PDEX.
Pro-Dex, Inc. filed a current report to share that it is releasing its financial results for the fourth fiscal quarter and fiscal year ended June 30, 2025. On September 4, 2025, the company issued a press release describing this performance, which is included as Exhibit 99.1. The company notes that the financial information in this item and the press release is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029–2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.
Pro-Dex, Inc. disclosed that its Compensation Committee approved discretionary cash bonuses for its two senior executives. On August 14, 2025, the committee granted a $50,000 bonus to Chief Financial Officer Alisha K. Charlton and a $70,000 bonus to Chief Executive Officer Richard L. Van Kirk. The company states that Mr. Van Kirk’s bonus was based on Pro-Dex’s sales growth and fiscal 2025 financial performance exceeding plan. Both bonuses will be paid in cash in the next bi-weekly pay period, with a pay date of August 21, 2025.